Rousseau, B., Guillemin, A., Duvoux, C., Neuzillet, C., Tlemsani, C., Compagnon, P., Azoulay, D., Salloum, C., Laurent, A., de la Taille, A., Salomon, L., Cholley, I., Haioun, C., Dupuis, J., Wolkenstein, P., Matignon, M., Grimbert, P., & Tournigand, C. (2019). optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma. International journal of cancer, 144(4), 886–896. http://access.bl.uk/ark:/81055/vdc_100076253749.0x00005d